Squarepoint
TGTX icon

Squarepoint’s TG Therapeutics TGTX Stock Holding History

Squarepoint’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,800
Closed -$499K – 4887
2025
Q3 		$499K Buy
13,800
+2,500
+22% +$82.3K ﹤0.01% 3234
2025
Q2 		$407K Sell
11,300
-400
-3% -$14.9K ﹤0.01% 3442
2025
Q1 		$461K Sell
11,700
-48,100
-80% -$1.62M ﹤0.01% 3378
2024
Q4 		$1.8M Buy
+59,800
New +$1.72M ﹤0.01% 2522

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Squarepoint's TGTX Position: Q1 2026 in Review

Squarepoint reduced its TG Therapeutics (TGTX) stake by 40% in Q1 2026, selling an estimated $10.1M and leaving 513,813 shares worth $17.1M. The position accounts for 0.02% of the portfolio, ranked #790.

Squarepoint first reported a position in TGTX in Q4 2015 and has held it in 22 quarters since. The position peaked at $25.4M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Squarepoint held 513,813 shares of TG Therapeutics worth $17.1M as of Q1 2026.
  • Squarepoint sold 338,709 TG Therapeutics shares in Q1 2026, an estimated $10.1M.
  • TG Therapeutics made up 0.02% of Squarepoint's portfolio in Q1 2026, its #790 holding.
  • Squarepoint first reported a position in TG Therapeutics in Q4 2015 and has held it in 22 quarters since.
  • Squarepoint's TG Therapeutics position peaked at $25.4M in Q4 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.